Skip to Content

Jennison Associates LLC owns 31.55% of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Jennison Associates LLC owns 31.55% of Prestige Consumer Healthcare Inc. (NYSE:PBH)

The most recent Form 13F filing that the company made with the SEC revealed that during the third quarter, Jennison Associates LLC increased the percentage of its holdings in Prestige Consumer Healthcare Inc. (NYSE: PBH) by 40.7%. The corporation bought an additional 183,121 shares of the company’s stock during the quarter, bringing the total number of shares it owns to 633,188. The most recent report that Jennison Associates LLC submitted to the SEC indicated that the company held Prestige Consumer Healthcare for approximately 1.27% of its market value, which was determined to be $31,552,000.

Other institutional investors have also adjusted the proportion of the business they own now; these adjustments were made in light of recent events. By purchasing additional shares of Prestige Consumer Healthcare during the second quarter, Ritholtz Wealth Management was able to boost the value of its stock holdings by 22.9%. Ritholtz Wealth Management now holds 9,022 shares of the company’s stock, valued at $530,000, following the acquisition of an additional 1,679 shares during the period in question. EverSource Wealth Advisors LLC increased the proportion of its holdings in Prestige Consumer Healthcare, owned by 272.9% during the second quarter of 2018. EverSource Wealth Advisors LLC now holds 1,622 shares of the company’s stock following the acquisition of an additional 1,187 shares over the preceding three months. Each share of the company’s stock is currently valued at $96,000. During the second quarter, Connor Clark & Lunn Investment Management Ltd. made a 144.6% increase in the amount of Prestige Consumer Healthcare stock held by the investment management firm. Connor Clark & Lunn Investment Management Ltd. now holds 38,406 shares of the company’s stock, following the acquisition of an additional 22,703 shares during the most recent quarter. The value of the company’s stock is currently estimated to be $2,258,000. Congress Asset Management Company, MA, increased the percentage of Prestige Consumer Healthcare shares it owned by 60.0% during the second quarter. After purchasing an additional 20,530 shares during the company’s most recent fiscal quarter, Congress Asset Management Co., MA, now owns a total of 54,747 shares of the company’s stock, which has a value of $3,219,000. These shares were acquired during the most recent quarter of the company’s fiscal year. And finally, during the second quarter, EMC Capital Management made a 51.0% increase in the amount of Prestige Consumer Healthcare stock it owned, bringing its total percentage of ownership to 100%. EMC Capital Management now has 7,104 shares after purchasing an additional 2,400 in the most recent quarter. The current value of EMC Capital Management’s holdings in the company is estimated to be $418,000. The company shares are currently owned by hedge funds and other institutional investors, who together account for 99.98% of the total.

Several different equity analysts recently published a commentary on the PBH stock. In a research report published on StockNews.com on October 12, Prestige Consumer Healthcare was mentioned for the first time as the subject of coverage. The consensus recommendation for the stock was a “buy.” In a research report released on November 16, Canaccord Genuity Group announced that it would begin covering shares of Prestige Consumer Healthcare the following day. They encouraged investors to “buy” the stock and established a price objective of $71.00 per share. The “outperform” rating Oppenheimer has given to Prestige Consumer Healthcare was raised to $72.00, and the price objective they set for the stock was raised from $63.00 to $72.00. A published research note on Friday announced both of these alterations to the system. Canaccord Genuity Group issued a research note on November 17, announcing that they would start covering shares of Prestige Consumer Healthcare. The note was part of a larger publication. They recommend “buying” the stock and have established a price objective of $71.00 for the share price of the company’s common stock. Six equity research experts have suggested to investors that they should purchase the stock, whereas only one has suggested that they continue to hold onto it. The information from Bloomberg indicates that the company is currently rated as having a consensus recommendation of “Moderate Buy” and that the average price objective is $71.00.

At the opening of trading on Tuesday, the price of PBH was $66.62 per share on the NYSE. Over the previous year, Prestige Consumer Healthcare Inc.’s stock price ranged from a low of $48.51 to a high of $67.18 at various points. The company has a price-to-earnings ratio of 1.98, a price-to-earnings-to-growth ratio of 16.17, and a beta value of 0.57. It is valued at $3.30 billion. According to the price-to-earnings-to-growth ratio, the company is forecast to experience growth at a rate of 1.98 over the next few years. The ratio of the current ratio to the quick ratio is 1.29, while the ratio of the current ratio to the quick ratio is 2.21. The ratio of debt to equity is 0.89. The moving average of the company’s performance over the past 200 days is $57.09, while the moving average over the past 50 days is $61.72.

On November 3, the most recent quarterly earnings report made public was for Prestige Consumer Healthcare, which is listed on the New York Stock Exchange (NYSE) under the symbol “PBH.” The company announced earnings per share for the quarter of $1.02, which is $0.02 higher than the consensus projection of $1.00 based on the work of industry analysts. According to projections made by market analysts, revenue for the company’s most recent fiscal quarter was expected to fall somewhere between $282.93 million to $289.27 million. Both the return on equity and the net margin for the company came in at 12.88 percent for Prestige Consumer Healthcare, with 18.83 percent being the net margin. Profits for the year at Prestige Consumer Healthcare Inc. are expected to come in at 4.2 cents per share, according to projections made by analysts who follow the industry.

All of the over-the-counter (OTC) health and personal care products that Prestige Consumer Healthcare Inc. creates, manufactures, markets, advertises, distributes, and sells in the United States and internationally are distributed and marketed by the company’s subsidiaries. This includes both domestically and internationally sold products. The business is organized into two distinct divisions: the North American OTC Healthcare Division and the International OTC Healthcare Division.

Tags

Leave a comment

Your email address will not be published. Required fields are marked *